mirror of https://github.com/Zelo72/adguard
Atrial Septal Defect Market Is Expected To Reach USD 4.7 Billion By 2032. #774
Loading…
Reference in New Issue
No description provided.
Delete Branch "%!s(<nil>)"
Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?
Market Overview: The global market for atrial septal defects (ASD) was valued at USD 2.4 billion in 2022 and is projected to reach USD 4.7 billion by 2032, with a compound annual growth rate (CAGR) of 8.6% during the forecast period. Factors such as the prevalence of congenital heart defects (CHD), advancements in minimally invasive treatments, and the increasing demand for ASD closure devices are driving the growth of the market.
The prevalence of CHD, affecting approximately 1% of live births in the United States according to the American Heart Association, with ASD accounting for about 10% of CHD cases, significantly influences the ASD market. Additionally, the preference for minimally invasive procedures among patients and healthcare professionals is boosting the market, as these methods offer benefits such as shorter hospital stays, faster recovery times, and minimal scarring. Technological advancements have led to the development of transcatheter ASD closure devices, revolutionizing ASD treatment and reducing the reliance on conventional surgical techniques.
Get a sample copy of the Atrial Septal Defect Market report: https://www.reportsanddata.com/download-free-sample/6915
Growing healthcare costs and increased awareness of ASD treatment options are expected to further drive market growth. Governments are taking initiatives to raise awareness and improve access to treatment for ASD and other CHD. Emerging markets, particularly in countries like Brazil, China, and India, present lucrative opportunities for market expansion due to the high prevalence of CHD and rising healthcare investments. However, market growth may be hindered by the high cost of ASD closure operations and devices, as well as restrictive reimbursement policies.
Regulatory Landscape: Regulatory oversight for medical devices used in diagnosing and treating ASDs varies by region. In the United States, the Food and Drug Administration (FDA) regulates such devices through its Center for Devices and Radiological Health (CDRH). Similarly, the European Union has established standards under the Medical Device Directive 93/42/EEC. The Global Harmonization Task Force (GHTF) provides a basis for regulatory requirements worldwide, while the WHO's Framework Convention on Tobacco Control (FCTC) and International Classification of Diseases (ICD) support tobacco control efforts and standardized disease classification, respectively.
Diagnosis Outlook: ASD, a congenital heart defect characterized by a hole in the septum dividing the heart's upper chambers, can lead to various complications such as heart failure and stroke. Diagnosis methods include Magnetic Resonance Imaging, transesophageal echocardiography, and others. Transthoracic Echocardiography, a non-invasive procedure utilizing sound waves to produce images of the heart's structure and function, dominated the ASD market in 2021 due to its convenience and effectiveness.
Therapy Type Outlook: Treatment options for ASD include surgical closure, catheter-based closure, and others. Surgical closure, involving open-heart surgery to patch the defect, has historically been the preferred method for complex ASDs. However, catheter-based closure techniques are gaining prominence due to their minimally invasive nature, resulting in shorter hospital stays and quicker recovery times. Complementary therapies, such as medication and lifestyle adjustments, may also be recommended to manage symptoms.